Docetaxel-Induced Fatal Interstitial Pneumonitis in a Patient with Castration-Resistant Prostate Cancer
暂无分享,去创建一个
Wun-Jae Kim | W. Kim | S. Yun | H. Kang | Yong-June Kim | B. Min | Sang Cheol Lee
[1] Y. Maehara,et al. Severe interstitial pneumonitis associated with the administration of taxanes , 2010, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[2] C. Grande,et al. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[3] C. Wiedermann,et al. Fatal Interstitial Pneumonitis Associated with Docetaxel Administration in a Patient with Hormone-Refractory Prostate Cancer , 2006, Tumori.
[4] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[5] W. Read,et al. Severe interstitial pneumonitis associated with docetaxel administration , 2002, Cancer.
[6] R. Perng,et al. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere) , 2001, British Journal of Cancer.
[7] F. Fossella. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. , 1999, Seminars in oncology.
[8] H. Choy,et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] C. Croce,et al. Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.
[10] T. Taguchi,et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.